Please Wait

Applying Filters...

Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Ipratropium Bromide

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

27 API Suppliers, 8 USDMF, 9 CEP/COS, 1 JDMF, 5 EU WC, 9 KDMF, 14 NDC API, 21 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

188 FDF Dossiers, 45 FDA Orange Book, 81 Europe, 18 Canada, 5 Australia, 23 South Africa, 16 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SPRAY, METERED;NASAL - 0.021MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SPRAY, METERED;NASAL - 0.042MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INHALATION - EQ 0.083% BASE;0.017% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

5 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

4 Parenteral, 2 Solubilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 15 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 56 Regulatory FDF Prices

MARKET PLACE

10 APIs, 6 FDF Dossiers, 1 EXCIPIENTS

PATENTS & EXCLUSIVITIES

6 US Patents, 1 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 EDQM, 4 USP, 9 Others

$ Xls download

Filters

Log in to access your PharmaMiles and download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
28/03/2025	Aarti Pharmalabs	India	AARTI PHARMALABS LTD	21179	IPRATROPIUM BROMIDE	2007-12-15	Active	II	N/A
28/03/2025	Neuland Laboratories	India	NEULAND LABORATORIES LTD	15130	IPRATROPIUM BROMIDE USP	2000-11-06	Active	II	Complete	2014-01-15	2014-01-03

Contact us
to update this info

Ipratropium Bromide

Ipratropium Bromide

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

27 API Suppliers

8 USDMF

9 CEP/COS

1 JDMF

5 EU WC

9 KDMF

14 NDC API

21 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

188 FDF Dossiers

45 FDA Orange Book

81 Europe

18 Canada

5 Australia

23 South Africa

16 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SPRAY, METERED;NASAL - 0.021MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SPRAY, METERED;NASAL - 0.042MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INHALATION - EQ 0.083% BASE;0.017% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

5 Actylis

1 Finar

EXCIPIENTS BY APPLICATIONS

4 Parenteral

2 Solubilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow

15 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

56 Regulatory FDF Prices

MARKET PLACE

10 APIs

6 FDF Dossiers

1 EXCIPIENTS

PATENTS & EXCLUSIVITIES

6 US Patents

1 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 EDQM

4 USP

9 Others

Filters

SPRAY, METERED;NASAL - 0.021MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SPRAY, METERED;NASAL - 0.042MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION;INHALATION - EQ 0.083% BASE;0.017% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons